BMP9 Protein Protects Against Iron-Induced Bone Loss Through Novel Cellular Pathway

This groundbreaking study reveals how excess iron contributes to osteoporosis and identifies a promising therapeutic approach. Iron accumulation, increasingly recognized as a factor in bone disease, triggers ferroptosis - a form of cell death driven by iron-dependent lipid damage - in bone marrow stem cells that normally build new bone tissue.

Researchers investigated BMP9 (Bone Morphogenetic Protein 9), known for promoting bone formation, to see if it could counteract iron-induced bone damage. Using human samples, cell cultures, and mouse models, they demonstrated that BMP9 protects bone-forming cells through a previously unknown molecular pathway.

The key discovery involves a three-protein cascade: BMP9 increases USP10 enzyme production, which prevents degradation of FOXO1 transcription factor, allowing it to activate GPX4 - a crucial antioxidant protein that blocks ferroptosis. In iron-overloaded mice, BMP9 treatment significantly reduced bone cell death, improved antioxidant defenses, and enhanced bone formation capacity.

Human data showed that higher serum iron levels correlated with lower bone density in the spine and hip, confirming the clinical relevance. Laboratory experiments revealed that BMP9 treatment restored normal bone-building activity in cells exposed to toxic iron levels, while also reducing harmful oxidative stress markers.

These findings have important implications for treating osteoporosis, particularly in patients with iron overload conditions like hemochromatosis or those receiving iron supplementation. The research suggests that targeting the USP10/FOXO1/GPX4 pathway could provide a new therapeutic strategy for preventing and treating iron-related bone loss, potentially through BMP9-based treatments or drugs that mimic its protective effects.